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In January, Harold Varmus will
begin the next stage in an unusual
career. He’s gone from English
literature to medicine to bench
science to Washington science
bureaucrat, and now he becomes the
well-paid (some would say
extremely well-paid) president of a
private, not-for-profit treatment and
research facility, the Memorial Sloan
Kettering Cancer Center in New
York. He’s succeeded in everything
else he’s tried, so it’s a good bet he’ll
succeed in this latest role, too.
It might seem like the jump from
English to medicine was the biggest
one, but Varmus will tell you that an
even bigger leap was going from
scientist to science bureaucrat. By
his own admission, just a few years
before becoming director of the
NIH in 1992 his interest in the
politics of science was practically
non-existent. He was running a
successful lab at the University of
California, San Francisco and, with
Michael Bishop, he won the 1989
Nobel Prize for Physiology or
Medicine for his work on viruses and
their relationship to oncogenes.
But as he tells it, in the late
1980s and early 1990s, several events
occurred that brought Varmus off the
political sidelines. First, a quirk in
funding patterns led to an unusually
low success rate for new grants,
especially among first-time
applicants. Second, there was a
series of misconduct scandals that
seemed to tarnish the public’s
traditionally high regard for
scientists. And finally, the Reagan
administration seemed bent on
shifting the support for science from
basic to applied research as a way of
justifying the multi-billion dollar
federal research budget.
Varmus felt he couldn’t sit idly by
in the face of these threats. What’s
more, his newly bestowed Nobel
Prize gave him unusual access to
both the media and the political
establishment. Varmus entered the
fray. In part, he blames two people
for getting him engaged: his
colleagues Marc Kirschner and Bruce
Alberts, both then at UCSF.
Varmus says Alberts in particular
convinced him to take a more active
role in solving the
funding problems
facing scientists. And,
says Varmus, “when
Bruce, as newly
elected President of
the NAS, was asked
to chair a search
committee to find a
new NIH Director,
my fate was sealed.”
Although
outsiders are
frequently hauled
into Washington, it’s
rare to put someone
at the top of an
11 billion dollar
federal agency with no experience of
managing anything larger than a
personal laboratory.
But those who knew him were
convinced Varmus could accomplish
anything he set his mind to. “I think
Harold not only proved us all right,”
says UCSF’s Keith Yamamoto, “but
far exceeded anything any of us
expected. He turned out not only to
be a capable administrator, even
though he lacked that experience,
but he has just done a masterful job.”
Yamamoto says being NIH director
did not change Varmus’ style all that
much. “What Harold did was to go
there as a scientist and say, ‘look, we
can do things the way we do in the
laboratory, we can do experiments,
and if they work, we can implement
them.’’ Yamamoto says one of his big
achievements was to start to overhaul
the peer review process for
approving grants. According to
Yamamoto the new system will allow
for more innovative if more risky
research to have a better chance of
being funded.
Another project with broad
implications is Varmus’ plan to put
all biomedical research papers
online — by means of the new NIH
publishing venture, PubMed
Central. Tom Pollard, the president
of the Salk Institute in La Jolla, says
the project reflects the kind of
forward thinking Varmus is capable
of. “The idea is to allow the
scientific community
all around the world
access to the major
publications in an
electronic form so
that anybody could
have access to any
piece of information
without restriction,
whether they were in
a small institution
here in the US or in
any other part of the
world.” PubMed
Central will be
launched early next
year by the NIH,
albeit as a somewhat
watered-down version of the
original idea.
Although Varmus won
widespread praise for his leadership
at NIH, both from politicians and
fellow science bureaucrats, he never
stopped behaving more like a
scientist. He maintained an active
laboratory within the National
Cancer Institute, and rode his
bicycle to work, frequently showing
up at his office in sweaty clothes,
changing into a suit only if the day’s
activities required.
Varmus is an intense man — not
surprising considering all he
manages to accomplish in a given
day. He can intimidate lesser minds,
and has little patience for sloppy
thinking. “He’s not what I would
describe as cuddly,” remarks one
senior NIH official, “but if he thinks
you’re right, he’ll be one of your
fiercest defenders.”
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Harold Varmus — now making
another leap
Varmus can also be charming and
droll. At a recent White House event,
Hillary Clinton introduced Varmus as
the “outgoing head of NIH,” to
which Varmus replied, “I assume by
‘outgoing’ you meant I’m leaving, as
opposed to my social behavior.”
Varmus plans to continue his
scientific research at Memorial Sloan
Kettering. He says he wasn’t chafing
to leave NIH, but when the top job
at the New York cancer center came
along, he felt he had to jump at it. “I
think the next decade or two will be
a crucial time for moving our basic
understanding of cancer into the
clinic in a very powerful way,” says
Varmus. “To be at an institution that
has a strong science base and also a
remarkable patient population and a
strong history of doing clinical trials
and taking good care of patients is an
ideal place to be as that revolution
occurs.” It’s a revolution that Varmus
has had a large part in fomenting.
Joseph Palca is a correspondent with
National Public Radio, and is currently on a
Kaiser Family Foundation media fellowship.
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The Human Genome
Project
What is it famous for? It depends who
you talk to but its most ardent
supporters think it’s the most
important biology project ever.
Walter Gilbert hailed it as biology’s
‘Holy Grail’. Francis Collins says it’s
more important than the moon race,
whereas Eric Lander draws
comparisons with Mendeleev’s
periodic table of the elements.
How did it start? Two prominent
scientists deserve most of the credit
for conceiving the Human Genome
Project (HGP) in the mid 1980s.
University of California biologist
Robert Sinsheimer organized an
influential symposium in 1985 that
got the ball rolling. Nobel laureate
Renatto Dulbecco really pushed
matters forward when he argued in a
1986 editorial in Science for a
comprehensive genome project, to
help in the fight against cancer. 
Hasn’t it proved to be controversial?
Yes, mainly because of the cost.
Three billion dollars — or $1 per
DNA base — is a lot of money, even
spread over 15 years, and some
senior figures in the biomedical
community were worried that many
worthwhile projects would have to
be sacrificed to find the funds. But
the US Congress was persuaded that
the potential advances in finding
disease genes would justify new
investment. The HGP kicked off in
1990, as a joint project between the
National Institutes of Health and the
US Department of Energy, with
sizeable support from Europe and
Japan. About one third of the
sequencing is being done at the
Sanger Centre in the UK, funded by
the Wellcome Trust.
Is the project on schedule? It is now,
although there have been a few
headaches. The French group at
Généthon did a great job of building
a comprehensive genetic map of the
human genome, comprised of
thousands of polymorphic markers,
but they and others found
difficulties in making the
corresponding physical map.
Improved vectors have now enabled
reliable physical maps for all 23 pairs
of chromosomes to be constructed.
What’s the current state of play? The
sequence of the first complete
chromosome — chromosome 22 —
was published in Nature this month.
It contains more than 30 million
bases of sequence and includes
several hundred genes. Nearly 15%
of the human genome sequence is
now complete, and another 20% is
finished in draft form. Francis
Collins, chief of the Human Genome
Project, plans to issue a “rough
draft”, comprising 90% of the human
genome, in the spring of 2000 and
hopes to wrap up the sequence by
2003. (For the latest progress, see
www.ornl.gov/hgmis/project/progress.html.)
So, what about the commercial side?
More controversy. In 1998, the
infamous Craig Venter formed a new
company called Celera Genomics,
based in Gaithersburg, Maryland,
that aims to sequence the human
genome years ahead of the HGP.
What, is Venter nuts? Apparently not.
Instead of mapping each
chromosome, Celera is using the
shotgun sequencing method. The
company has about 300
state-of-the-art ABI PRISM 3700
capillary DNA sequencers, which not
only are the fastest machines on the
market but need almost no human
maintenance. They can generate
1 million bases of sequence in
24 hours. The raw sequence data will
be assembled using an $80 million
mainframe computer specially built
for Celera, and will probably take
about three months.
What is Celera doing with the data?
The company says it will release the
sequence for free, but sell access to
its customized database to its
pharmaceutical clients. It says it will
patent no more than a few hundred
human genes, although preliminary
applications have already been filed
for several thousand genes. Not
surprisingly, supporters of the HGP
are up in arms about this, arguing that
the human genome sequence must
be publicly owned.
Who will win the race? Venter claims
that by the summer of 2000, Celera
will have sequenced 9 billion bases
of human DNA, or enough to
identify more than 90% of human
genes. The company might finish
the full sequence in 2001. But many
are sceptical of Celera’s ability to
piece together the full human
sequence, and are worried that others
will be left the thankless task of
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filling thousands of gaps in the
sequence. At a Congressional hearing
in 1998, Maynard Olsen, head of the
HGP effort at the University of
Washington, challenged Venter to
“Show me the data!”. Venter plans to
do just that, when he publishes the
completed genome sequence of
Drosophila melanogaster early in 2000.
What will the sequence tell us? The
first priority is to determine the
identity, if not the actual function, of
all human genes. Most textbooks put
the number of human genes at
100,000, but another genomics
company, Incyte Pharmaceuticals,
says there might be more like
140,000. Sequence homologies with
the completed genomes of yeast,
Drosophila and other organisms will
be invaluable. These data will be
coupled with information about gene
expression, protein structure and
metabolic pathways to help reveal
physiological function. There is also
intense interest in cataloguing sites
of sequence variation between
individuals. Researchers are
assembling thousands of single
nucleotide polymorphisms (SNPs) to
rapidly screen families and
populations for disease genes. Just in
the past few months, pharmaceutical
companies have touted discoveries of
genes underlying psoriasis, diabetes
and migraine. This might be the start
of the much-vaunted leap in our
ability to diagnose, and
treat, common human diseases.
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Win a digital camera
The Current Biology
Photomicrography
Competition
Closing date 25 Feb 2000. For details:
www.current-biology.com/cbphotocomp.html
Seeds of Arabidopsis thaliana,
showing the detailed morphology of
the seed coat. Genetic studies show
that the seed coat influences seed
development and germination. For
example, mutants with defects in
pigment biosynthesis produce seeds
that not only are paler but also have
reduced dormancy. The scanning
electron micrograph has been
coloured to emphasize
morphological features. Image
provided by Dennis Kunkel, Pacific
Biomedical Research Center,
University of Hawaii at Manoa,
Honolulu, Hawaii 96822, USA.
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Like peas in a pod
